Morris M - Search Results

1

Splenic imaging with ultrasmall superparamagnetic iron oxide ferumoxtran-10 (AMI-7227): preliminary observations.

Harisinghani MG, Saini S, Weissleder R, Rubin D, deLange E, Harms S, Weinreb J, Small W, Sukerkar A, Brown JJ, Zelch J, Lucas M, Morris M, Hahn PF. Harisinghani MG, et al. Among authors: morris m. J Comput Assist Tomogr. 2001 Sep-Oct;25(5):770-6. doi: 10.1097/00004728-200109000-00017. J Comput Assist Tomogr. 2001. PMID: 11584239

2

Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data.

Sharma R, Saini S, Ros PR, Hahn PF, Small WC, de Lange EE, Stillman AE, Edelman RR, Runge VM, Outwater EK, Morris M, Lucas M. Sharma R, et al. Among authors: morris m. J Magn Reson Imaging. 1999 Feb;9(2):291-4. doi: 10.1002/(sici)1522-2586(199902)9:2<291::aid-jmri21>3.0.co;2-#. J Magn Reson Imaging. 1999. PMID: 10077027 Clinical Trial.

3

Ferumoxtran-10, a superparamagnetic iron oxide as a magnetic resonance enhancement agent for imaging lymph nodes: a phase 2 dose study.

Hudgins PA, Anzai Y, Morris MR, Lucas MA. Hudgins PA, et al. AJNR Am J Neuroradiol. 2002 Apr;23(4):649-56. AJNR Am J Neuroradiol. 2002. PMID: 11950660 Free PMC article. Clinical Trial.

4

Preliminary clinical experience with AMI 227.

McLachlan SJ, Morris M, Lucas MA, Baum LM. McLachlan SJ, et al. Among authors: morris m. Acad Radiol. 1996 Aug;3 Suppl 2:S295-6. doi: 10.1016/s1076-6332(96)80561-7. Acad Radiol. 1996. PMID: 8796584 Clinical Trial. No abstract available.

5

Safety and optimum concentration of a manganese chloride-based oral MR contrast agent.

Bernardino ME, Weinreb JC, Mitchell DG, Small WC, Morris M. Bernardino ME, et al. Among authors: morris m. J Magn Reson Imaging. 1994 Nov-Dec;4(6):872-6. doi: 10.1002/jmri.1880040620. J Magn Reson Imaging. 1994. PMID: 7865949

6

Phase I clinical evaluation of a new iron oxide MR contrast agent.

McLachlan SJ, Morris MR, Lucas MA, Fisco RA, Eakins MN, Fowler DR, Scheetz RB, Olukotun AY. McLachlan SJ, et al. Among authors: morris mr. J Magn Reson Imaging. 1994 May-Jun;4(3):301-7. doi: 10.1002/jmri.1880040313. J Magn Reson Imaging. 1994. PMID: 8061425 Clinical Trial.

7

Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck.

Anzai Y, McLachlan S, Morris M, Saxton R, Lufkin RB. Anzai Y, et al. Among authors: morris m. AJNR Am J Neuroradiol. 1994 Jan;15(1):87-94. AJNR Am J Neuroradiol. 1994. PMID: 7511324 Free PMC article. Clinical Trial.

8

Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer.

Anzai Y, Blackwell KE, Hirschowitz SL, Rogers JW, Sato Y, Yuh WT, Runge VM, Morris MR, McLachlan SJ, Lufkin RB. Anzai Y, et al. Among authors: morris mr. Radiology. 1994 Sep;192(3):709-15. doi: 10.1148/radiology.192.3.7520182. Radiology. 1994. PMID: 7520182

9

Efficacy of gadoteridol for contrast-enhanced magnetic resonance imaging in children.

Ball WS Jr, Parker JR, Davis PC, Glasier CM, Morris MR. Ball WS Jr, et al. Among authors: morris mr. Invest Radiol. 1992 Aug;27 Suppl 1:S45-52. Invest Radiol. 1992. PMID: 1506153 Clinical Trial.

10

ACR Appropriateness Criteria® Workup of Pleural Effusion or Pleural Disease.

Expert Panel on Thoracic Imaging; Morris MF, Henry TS, Raptis CA, Amin AN, Auffermann WF, Hatten BW, Kelly AM, Lai AR, Martin MD, Sandler KL, Sirajuddin A, Surasi DS, Chung JH. Expert Panel on Thoracic Imaging, et al. Among authors: morris mf. J Am Coll Radiol. 2024 Jun;21(6S):S343-S352. doi: 10.1016/j.jacr.2024.02.013. J Am Coll Radiol. 2024. PMID: 38823955

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

5,682 results

Search Page